242 related articles for article (PubMed ID: 23504607)
1. Thrombosis in systemic lupus erythematosus: role of impaired fibrinolysis.
Dhillon PK; Adams MJ
Semin Thromb Hemost; 2013 Jun; 39(4):434-40. PubMed ID: 23504607
[TBL] [Abstract][Full Text] [Related]
2. [Status of fibrinolysis in systemic lupus erythematosus].
Ihle E; Ziemer S
Folia Haematol Int Mag Klin Morphol Blutforsch; 1986; 113(1-2):184-90. PubMed ID: 2427400
[TBL] [Abstract][Full Text] [Related]
3. Antibodies to fibrin-bound tissue-type plasminogen activator in systemic lupus erythematosus are associated with Raynaud's phenomenon and thrombosis.
Salazar-Paramo M; Garcia de la Torre I; Fritzler MJ; Loyau S; Anglés-Cano E
Lupus; 1996 Aug; 5(4):275-8. PubMed ID: 8869898
[TBL] [Abstract][Full Text] [Related]
4. Haemostasis in oral surgery--the possible pathogenetic implications of oral fibrinolysis on bleeding. Experimental and clinical studies of the haemostatic balance in the oral cavity, with particular reference to patients with acquired and congenital defects of the coagulation system.
Sindet-Pedersen S
Dan Med Bull; 1991 Dec; 38(6):427-43. PubMed ID: 1802633
[TBL] [Abstract][Full Text] [Related]
5. Fibrinolysis in health and disease: severe abnormalities in systemic lupus erythematosus.
Glas-Greenwalt P; Kant KS; Allen C; Pollak VE
J Lab Clin Med; 1984 Dec; 104(6):962-76. PubMed ID: 6239000
[TBL] [Abstract][Full Text] [Related]
6. The fibrinolytic system in neoplasia.
Bell WR
Semin Thromb Hemost; 1996; 22(6):459-78. PubMed ID: 9122711
[TBL] [Abstract][Full Text] [Related]
7. [Dysfunction of fibrinolysis as a risk factor of thrombosis].
Kołodziejczyk J; Wachowicz B
Pol Merkur Lekarski; 2009 Oct; 27(160):341-5. PubMed ID: 19928667
[TBL] [Abstract][Full Text] [Related]
8. A precise and rapid microtitre plate clot lysis assay: methodology, kinetic modeling and measurement of catalytic constants for plasminogen activation during fibrinolysis.
Jones AJ; Meunier AM
Thromb Haemost; 1990 Nov; 64(3):455-63. PubMed ID: 2128976
[TBL] [Abstract][Full Text] [Related]
9. Differential role of components of the fibrinolytic system in the formation and removal of thrombus induced by endothelial injury.
Matsuno H; Kozawa O; Niwa M; Ueshima S; Matsuo O; Collen D; Uematsu T
Thromb Haemost; 1999 Apr; 81(4):601-4. PubMed ID: 10235447
[TBL] [Abstract][Full Text] [Related]
10. Fibrinolytic potential and antiphospholipid antibodies in systemic lupus erythematosus and other connective tissue disorders.
Jurado M; Páramo JA; Gutierrez-Pimentel M; Rocha E
Thromb Haemost; 1992 Nov; 68(5):516-20. PubMed ID: 1455397
[TBL] [Abstract][Full Text] [Related]
11. Molecular mechanisms of fibrinolysis and their application to fibrin-specific thrombolytic therapy.
Collen D
J Cell Biochem; 1987 Feb; 33(2):77-86. PubMed ID: 3553213
[TBL] [Abstract][Full Text] [Related]
12. Disturbances in the tissue plasminogen activator/plasminogen activator inhibitor (TPA/PAI) system in systemic lupus erythematosus.
Ruiz-Argüelles GJ; Ruiz-Argüelles A; Lobato-Mendizábal E; Díaz-Gomez F; Pacheco-Pantoja E; Drenkard C; Alarcón-Segovia D
Am J Hematol; 1991 May; 37(1):9-13. PubMed ID: 1902623
[TBL] [Abstract][Full Text] [Related]
13. Physiologic regulation and pathologic disorders of fibrinolysis.
Francis CW; Marder VJ
Hum Pathol; 1987 Mar; 18(3):263-74. PubMed ID: 3546075
[TBL] [Abstract][Full Text] [Related]
14. The role of fibrinolytic factors in ischaemia.
Pandolfi M; al-Rushood A
Eye (Lond); 1991; 5 ( Pt 2)():159-69. PubMed ID: 2070877
[TBL] [Abstract][Full Text] [Related]
15. Predisposing factors to thrombosis in systemic lupus erythematosus: possible relation to endothelial cell damage.
Angles-Cano E; Sultan Y; Clauvel JP
J Lab Clin Med; 1979 Aug; 94(2):312-23. PubMed ID: 458249
[TBL] [Abstract][Full Text] [Related]
16. Fibrinolysis abnormalities in systemic lupus erythematosus and their relation to vasculitis.
Awada H; Barlowatz-Meimon G; Dougados M; Maisonneuve P; Sultan Y; Amor B
J Lab Clin Med; 1988 Feb; 111(2):229-36. PubMed ID: 3123585
[TBL] [Abstract][Full Text] [Related]
17. Lupus nephritis with thrombosis and abnormal fibrinolysis: effect of ancrod.
Kant KS; Pollak VE; Dosekun A; Glas-Greenwalt P; Weiss MA; Glueck HI
J Lab Clin Med; 1985 Jan; 105(1):77-88. PubMed ID: 3968467
[TBL] [Abstract][Full Text] [Related]
18. Fibrinolysis in patients with acute ischaemic heart disease. With particular reference to systemic effects of tissue-type plasminogen activator treatment on fibrinolysis, coagulation and complement pathways.
Munkvad S
Dan Med Bull; 1993 Sep; 40(4):383-408. PubMed ID: 8222763
[TBL] [Abstract][Full Text] [Related]
19. In vitro clot lysis as a potential indicator of thrombus resistance to fibrinolysis--study in healthy subjects and correlation with blood fibrinolytic parameters.
Colucci M; Scopece S; Gelato AV; Dimonte D; Semeraro N
Thromb Haemost; 1997 Apr; 77(4):725-9. PubMed ID: 9134650
[TBL] [Abstract][Full Text] [Related]
20. [Biochemical and physiologic principles of tissue-type plasminogen activator].
Lill H
Z Gesamte Inn Med; 1987 Sep; 42(17):478-86. PubMed ID: 3120429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
